当前位置:Public Access >页面
Chinese/English
A 24-Week, Open-label, Randomized, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Gan & Lee Injection (Ruixiulin) to NovoRapid®, Both in Combination with Metformin in Adult Subjects with Type 1 or Type 2 Diabetes

ChiCTR注册号:

Reg No. in ChiCTR:

ChiCTR2000031290

研究题目:

A 24-Week, Open-label, Randomized, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Gan & Lee Injection (Ruixiulin) to NovoRapid®, Both in Combination with Metformin in Adult Subjects with Type 1 or Type 2 Diabetes

Study title:

A 24-Week, Open-label, Randomized, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Gan & Lee Injection (Ruixiulin) to NovoRapid®, Both in Combination with Metformin in Adult Subjects with Type 1 or Type 2 Diabetes

 注册状况:

 Registration:

True

注册机构:

中国临床试验注册中心

Name of the Registry:

Chinese Clinical Trial Registry

项目负责人:

中国临床试验注册中心

Corresponding person:

Chinese Clinical Trial Registry

电话:

Telephone:

010-83575662

电子邮件

Email

guoxh@medmail.com.cn

通讯地址:

北京市西城区西什库大街8号

Address:

No.8 Xishiku Street, Xicheng District, Beijing

邮政编码

Postcode

100034

项目负责人所有单位:

北京大学第一医院

Institution:

Peking University First Hospital

批准本研究的伦理委员会名称:

北京大学第一医院国家药物临床试验伦理委员会

Name of the ethic committee:

Peking University First Hospital National Drug Cli

研究疾病:

一型或二型糖尿病

Study Ailment:

Type 1 or Type 2 Diabetes Milletus

研究所处阶段:

Study phase:

Premarket

研究类型:

Type of Study:

Therapy Study

研究团队:

Research team:

研究实施地点:

Site of Study:

国家(地区):

中国

省(直辖市):

北京

市(区县):

北京

Country/Area:

China

Province:

Beijing

City:

Beijing
单位 北京大学第一医院
Institution Peking University First Hospital

预计起止时间:

Planned Duration:

2020/3/25 9:34:35-2020/3/25 9:34:35